Report Store mobile icon
Asia Pacific Influenza Treatment Market 2020-2030
Asia Pacific Influenza Treatment Market 2020-2030

2020

Asia Pacific Influenza Treatment Market 2020-2030

The Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic. Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country. Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Based on Influenza Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Table of Contents

  • 1 Introduction 5
  • 1.1 Industry Definition and Research Scope 5
  • 1.1.1 Industry Definition 5
  • 1.1.2 Research Scope 6
  • 1.2 Research Methodology 9
  • 1.2.1 Overview of Market Research Methodology 9
  • 1.2.2 Market Assumption 10
  • 1.2.3 Secondary Data 10
  • 1.2.4 Primary Data 10
  • 1.2.5 Data Filtration and Model Design 12
  • 1.2.6 Market Size/Share Estimation 13
  • 1.2.7 Research Limitations 14
  • 1.3 Executive Summary 15
  • 2 Market Overview and Dynamics 17
  • 2.1 Market Size and Forecast 17
  • 2.1.1 Impact of COVID-19 on the Market 18
  • 2.2 Major Growth Drivers 20
  • 2.3 Market Restraints and Challenges 24
  • 2.4 Emerging Opportunities and Market Trends 27
  • 2.5 Porter’s Fiver Forces Analysis 31
  • 3 Segmentation of Asia Pacific Market by Product Type 35
  • 3.1 Market Overview by Product Type 35
  • 3.2 Oseltamivir Phosphate 37
  • 3.3 Baloxavir Marboxil 38
  • 3.4 Peramivir 39
  • 3.5 Zanamivir 40
  • 3.6 Other Drugs 41
  • 4 Segmentation of Asia Pacific Market by Influenza Type 42
  • 4.1 Market Overview by Influenza Type 42
  • 4.2 Influenza A 44
  • 4.3 Influenza B 45
  • 4.4 Influenza C 46
  • 5 Segmentation of Asia Pacific Market by Administration Route 47
  • 5.1 Market Overview by Administration Route 47
  • 5.2 Oral Administration 49
  • 5.3 Other Administration Routes 50
  • 6 Segmentation of Asia Pacific Market by Distribution Channel 51
  • 6.1 Market Overview by Distribution Channel 51
  • 6.2 Retail Pharmacy 53
  • 6.3 Hospital Pharmacy 54
  • 6.4 Clinics 55
  • 6.5 Online Stores 56
  • 7 Asia-Pacific Market 2019-2030 by Country 57
  • 7.1 Overview of Asia-Pacific Market 57
  • 7.2 Japan 60
  • 7.3 China 63
  • 7.4 Australia 65
  • 7.5 India 67
  • 7.6 South Korea 69
  • 7.7 Rest of APAC Region 71
  • 8 Competitive Landscape 73
  • 8.1 Overview of Key Vendors 73
  • 8.2 New Product Launch, Partnership, Investment, and M&A 76
  • 8.3 Company Profiles 77
  • AstraZeneca Plc 77
  • BioCryst Pharmaceuticals Inc. 79
  • Biondvax 80
  • Daiichi Sankyo Company 81
  • F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 82
  • GlaxoSmithKline Plc 83
  • Mylan N.V 84
  • Natco Pharma Limited 85
  • Novartis AG 86
  • Sanofi 87
  • Seqirus 88
  • Teva Pharmaceutical Industries Limited 89
  • 9 Investing in Asia Pacific Market: Risk Assessment and Management 90
  • 9.1 Risk Evaluation of Asia Pacific Market 90
  • 9.2 Critical Success Factors (CSFs) 93
  • Related Reports and Products 96

Table 1. Snapshot of North America Digital Biomarkers Market, 2019-2030 18
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31
Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34
Table 7. Main Product Trends and Market Opportunities in North America Digital Biomarkers Market 37
Table 8. North America Digital Biomarkers Market by System Component, 2019-2030, $ mn 45
Table 9. North America Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 48
Table 10. North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 55
Table 11. North America Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 59
Table 12. North America Digital Biomarkers Market by Application, 2019-2030, $ mn 70
Table 13. North America Digital Biomarkers Market by Development Status, 2019-2030, $ mn 78
Table 14. North America Digital Biomarkers Market by End User, 2019-2030, $ mn 83
Table 15. North America Digital Biomarkers Market by Country, 2019-2030, $ mn 89
Table 16. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn 93
Table 17. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 93
Table 18. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn 93
Table 19. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn 96
Table 20. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 96
Table 21. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn 96
Table 22. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn 98
Table 23. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 98
Table 24. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn 98
Table 25. Breakdown of North America Market by Key Vendor, 2019, % 101
Table 26. Actigraph LLC: Company Snapshot 104
Table 27. Actigraph LLC: Business Segmentation 104
Table 28. Actigraph LLC: Product Portfolio 105
Table 29. Actigraph LLC: Revenue, 2016-2018, $ mn 105
Table 30. Actigraph LLC: Recent Developments 105
Table 31. Risk Evaluation for Investing in North America Market, 2019-2030 134
Table 32. Critical Success Factors and Key Takeaways 137

Figure 1. Research Method Flow Chart 9
Figure 2. Breakdown of Primary Research 11
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 15
Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, $ mn 17
Figure 6. Impact of COVID-19 on Business 18
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market 20
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 23
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 23
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market 24
Figure 11. Investment Opportunity Analysis 28
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Influenza Treatment Market 31
Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 35
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 36
Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 37
Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 38
Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, $ mn 39
Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 40
Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 41
Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 42
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 43
Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, $ mn 44
Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, $ mn 45
Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, $ mn 46
Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 47
Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 48
Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 49
Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 50
Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 51
Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 52
Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 53
Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 54
Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, $ mn 55
Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, $ mn 56
Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 58
Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 59
Figure 37. Influenza Treatment Market in Japan, 2019-2030, $ mn 61
Figure 38. Influenza Treatment Market in China, 2019-2030, $ mn 63
Figure 39. Influenza Treatment Market in Australia, 2019-2030, $ mn 65
Figure 40. Influenza Treatment Market in India, 2019-2030, $ mn 67
Figure 41. Influenza Treatment Market in South Korea, 2019-2030, $ mn 69
Figure 42. Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn 71
Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period 73

Related Tags

Related Reports

payment cards

Allows one individual to access the purchased report Read More

Allows all employees of an organization to access the purchased report. Internal sharing only Read More

Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More

Buy Now

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Rishika Gupta

Rishika Gupta

Team Lead- Business Development

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (27 July, 2024)
  • Notify To Team (27 July, 2024)
  • Report updation (28 July, 2024)
  • Report Quality Check (28 July, 2024)
  • Report Dispatch (29 July, 2024)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Asia Pacific Influenza Treatment Market 2020-2030

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.